SOUTH SAN FRANCISCO, Calif. - Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, announced that Sam Whiting, M.D., Ph.D., chief medical officer, will participate in a webcast panel titled 'Developing Therapies for the Next Immuno-Oncology Targets' at the William Blair 2021 Biotech Focus Conference on Wednesday, July 14, 2021 at 2:10 p.m. ET.

To access the live or archived recording of the discussion, please visit the investor section of the Tempest website at https://ir.tempesttx.com.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPAR?, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco and supported by notable healthcare investors. More information about Tempest can be found on the company's website at www.tempesttx.com.

Contact:

Investor

Sylvia Wheeler

Wheelhouse Life Science Advisors

E: swheeler@wheelhouselsa.com

Aljanae Reynolds

Wheelhouse Life Science Advisors

E: areynolds@wheelhouselsa.com

(C) 2021 Electronic News Publishing, source ENP Newswire